Ascendis Pharma (ASND) announced that it has submitted its new drug application to the FDA for TransCon CNP for the treatment of children with ...

Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday ... Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.

Er-Kim has extended its exclusive agreement with Ascendis Pharma, broadening the reach of three endocrinology treatments across multiple countries in Eurasia. This follows the initial exclusive ...

The potential upside from other products like Yorvipath and TransCon CNP is seen as a counterbalance to Skytrofa’s current underperformance. Ascendis Pharma’s pipeline includes TransCon CNP, a ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the ...

M.D., Executive Vice President and Chief Medical Officer at Ascendis Pharma. "In addition to once-weekly administration, these outcomes and a safety and tolerability profile comparable to placebo ...

COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration ...